Sector News

Europe’s pharma chiefs seek stronger China ties

September 29, 2014
Life sciences
Heavyweights from the European pharmaceutical industry have concluded a successful trip to China, aimed at strengthening ties with the sector and government in the country.
 
A high-level delegation from the European Federation of Pharmaceutical Industries and Associations have just returned from Beijing, including president and Sanofi chief executive Chris Viehbacher, EFPIA director-general Richard Bergstrom and the heads of UCB and Merck Serono, Roch Doliveux and Stefan Oschmann. They took part in a public conference on ‘translational medicine in a global world and a workshop on transparency and good governance, as well as an industry regulatory symposium.
 
Mr Viehbacher noted that China’s growing life sciences sector “is paving the way for the country to become an increasingly influential player in drug development”, adding that the visit “marks an important milestone in fostering understanding between international health care leaders and promoting awareness about the advancements taking place” in China.
 
Dr Oschmann stated that China’s “commitments to reform healthcare and further develop a stronger biopharmaceutical sector go hand in hand”. He claimed that “to improve patient access to high-quality healthcare and to become a truly global innovator, China should continue to work towards creating an environment that supports innovation”.  
 
EFPIA notes that China’s pharmaceutical output has increased by 719% since 2000 and venture capital investments in the sector have grown from $7 million to $491 million over the same period. A growing number of global drugmakers have set up R&D centres in China over the last few years, including AstraZeneca and Novo Nordisk in 2002, Eli Lilly and GlaxoSmithKline in 2003 and Roche in 2004; since then, Pfizer, Sanofi and Johnson & Johnson have also established research bases there, among others.
 
The visit came days after GSK was ordered to pay £297 million to the Chinese government after having been found guilty of bribing doctors to prescribe its medicines.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach